Drug Profile
Treprostinil - United Therapeutics Corporation
Alternative Names: TD-300 TYVASO® Inhalation System; 15AU; 15AU81; ARD-1500; ARD-1550; BW 15AU; BW 15AU81; BW A15AU; LRX 15; MD 711; MD-0701; OreniCell; OreniLeft; Orenitram; Remodulin; Sustained-release treprostinil - United Therapeutics; TD-100 TYVASO® Inhalation System; TransCon treprostinil; Treprost; Treprostenol; Treprostinil diolamine; Treprostinol; Tresprostinol diethanolamine; Tyvaso; U 62840; Uniprost; UT 15; UT-15C; UT-15C SRLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Pfizer
- Developer AOP Orphan Pharmaceuticals AG; Ascendis Pharma; Ferrer; Lee's Pharmaceutical; Mochida Pharmaceutical; United Therapeutics Corporation
- Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pulmonary arterial hypertension; Pulmonary hypertension
- Phase III Idiopathic pulmonary fibrosis
- Phase II Systemic scleroderma
- Discontinued Cancer; Chronic limb-threatening ischemia; Heart failure
Most Recent Events
- 27 Feb 2024 United Therapeutics Corporation announces intention to seek US FDA approval for Idiopathic pulmonary fibrosis and Pulmonary fibrosis
- 21 Feb 2024 United Therapeutics Corporation sued the US FDA regarding its approval process for Liquidia Corporation's new drug
- 02 Nov 2023 United Therapeutics initiates enrollment in the phase III TETON-PPF trial for Pulmonary fibrosis in USA (Inhalation) (NCT05943535)